Goldman Sachs’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.08B | Buy |
2,417,875
+663,757
| +38% | +$310M | 0.12% | 152 |
|
|
2025
Q4 | $795M | Buy |
1,754,118
+269,460
| +18% | +$116M | 0.1% | 182 |
|
|
2025
Q3 | $581M | Sell |
1,484,658
-447,102
| -23% | -$187M | 0.07% | 253 |
|
|
2025
Q2 | $860M | Buy |
1,931,760
+197,166
| +11% | +$90.9M | 0.12% | 153 |
|
|
2025
Q1 | $841M | Buy |
1,734,594
+332,860
| +24% | +$155M | 0.14% | 130 |
|
|
2024
Q4 | $564M | Buy |
1,401,734
+43,200
| +3% | +$20M | 0.09% | 201 |
|
|
2024
Q3 | $632M | Sell |
1,358,534
-703,965
| -34% | -$338M | 0.1% | 187 |
|
|
2024
Q2 | $967M | Buy |
2,062,499
+661,539
| +47% | +$287M | 0.16% | 110 |
|
|
2024
Q1 | $586M | Sell |
1,400,960
-83,974
| -6% | -$35.5M | 0.1% | 194 |
|
|
2023
Q4 | $604M | Sell |
1,484,934
-210,391
| -12% | -$77.7M | 0.11% | 179 |
|
|
2023
Q3 | $590M | Sell |
1,695,325
-120,547
| -7% | -$42.2M | 0.13% | 152 |
|
|
2023
Q2 | $639M | Buy |
1,815,872
+104,141
| +6% | +$35.1M | 0.14% | 135 |
|
|
2023
Q1 | $539M | Buy |
1,711,731
+39,358
| +2% | +$11.8M | 0.12% | 151 |
|
|
2022
Q4 | $483M | Sell |
1,672,373
-48,374
| -3% | -$14.7M | 0.12% | 166 |
|
|
2022
Q3 | $498M | Buy |
1,720,747
+673,107
| +64% | +$194M | 0.13% | 131 |
|
|
2022
Q2 | $295M | Sell |
1,047,640
-196,067
| -16% | -$52.5M | 0.07% | 253 |
|
|
2022
Q1 | $325M | Buy |
1,243,707
+56,330
| +5% | +$13.4M | 0.07% | 275 |
|
|
2021
Q4 | $261M | Sell |
1,187,377
-206,385
| -15% | -$40.1M | 0.05% | 369 |
|
|
2021
Q3 | $253M | Buy |
1,393,762
+15,745
| +1% | +$3.07M | 0.05% | 344 |
|
|
2021
Q2 | $278M | Sell |
1,378,017
-284,549
| -17% | -$59.5M | 0.06% | 300 |
|
|
2021
Q1 | $357M | Buy |
1,662,566
+101,920
| +7% | +$22.4M | 0.09% | 204 |
|
|
2020
Q4 | $369M | Sell |
1,560,646
-483,081
| -24% | -$111M | 0.09% | 192 |
|
|
2020
Q3 | $556M | Buy |
2,043,727
+543,029
| +36% | +$150M | 0.16% | 109 |
|
|
2020
Q2 | $436M | Sell |
1,500,698
-252,282
| -14% | -$68.4M | 0.13% | 137 |
|
|
2020
Q1 | $417M | Sell |
1,752,980
-115,419
| -6% | -$26.5M | 0.15% | 127 |
|
|
2019
Q4 | $409M | Buy |
1,868,399
+259,060
| +16% | +$52.4M | 0.1% | 192 |
|
|
2019
Q3 | $273M | Sell |
1,609,339
-350,181
| -18% | -$61.9M | 0.08% | 269 |
|
|
2019
Q2 | $359M | Sell |
1,959,520
-342,113
| -15% | -$59.8M | 0.1% | 187 |
|
|
2019
Q1 | $423M | Sell |
2,301,633
-244,307
| -10% | -$45.1M | 0.13% | 138 |
|
|
2018
Q4 | $422M | Sell |
2,545,940
-59,559
| -2% | -$10.3M | 0.13% | 123 |
|
|
2018
Q3 | $502M | Sell |
2,605,499
-746,306
| -22% | -$133M | 0.13% | 139 |
|
|
2018
Q2 | $570M | Sell |
3,351,805
-89,262
| -3% | -$13.8M | 0.15% | 112 |
|
|
2018
Q1 | $561M | Buy |
3,441,067
+210,866
| +7% | +$34.4M | 0.14% | 133 |
|
|
2017
Q4 | $484M | Buy |
3,230,201
+533,497
| +20% | +$79M | 0.12% | 169 |
|
|
2017
Q3 | $410M | Sell |
2,696,704
-82,840
| -3% | -$12.5M | 0.1% | 184 |
|
|
2017
Q2 | $358M | Sell |
2,779,544
-876,362
| -24% | -$105M | 0.09% | 201 |
|
|
2017
Q1 | $400M | Sell |
3,655,906
-226,338
| -6% | -$19.9M | 0.11% | 159 |
|
|
2016
Q4 | $286M | Buy |
3,882,244
+287,541
| +8% | +$23.4M | 0.08% | 238 |
|
|
2016
Q3 | $313M | Sell |
3,594,703
-42,704
| -1% | -$4.04M | 0.09% | 192 |
|
|
2016
Q2 | $313M | Sell |
3,637,407
-772,565
| -18% | -$66.8M | 0.1% | 180 |
|
|
2016
Q1 | $351M | Buy |
4,409,972
+1,540,048
| +54% | +$139M | 0.12% | 162 |
|
|
2015
Q4 | $361M | Buy |
2,869,924
+530,388
| +23% | +$64M | 0.11% | 171 |
|
|
2015
Q3 | $244M | Buy |
2,339,536
+717,467
| +44% | +$92.2M | 0.08% | 247 |
|
|
2015
Q2 | $200M | Sell |
1,622,069
-149,768
| -8% | -$18.9M | 0.06% | 344 |
|
|
2015
Q1 | $209M | Sell |
1,771,837
-98,221
| -5% | -$11.8M | 0.07% | 342 |
|
|
2014
Q4 | $222M | Sell |
1,870,058
-164,325
| -8% | -$18.5M | 0.07% | 323 |
|
|
2014
Q3 | $228M | Sell |
2,034,383
-785,372
| -28% | -$74.8M | 0.07% | 283 |
|
|
2014
Q2 | $267M | Sell |
2,819,755
-869,911
| -24% | -$61M | 0.08% | 259 |
|
|
2014
Q1 | $261M | Sell |
3,689,666
-762,239
| -17% | -$60.4M | 0.09% | 247 |
|
|
2013
Q4 | $331M | Sell |
4,451,905
-1,905,026
| -30% | -$133M | 0.11% | 187 |
|
|
2013
Q3 | $482M | Sell |
6,356,931
-388,244
| -6% | -$30.9M | 0.18% | 100 |
|
|
2013
Q2 | $540M | Buy |
+6,745,175
| New | +$497M | 0.21% | 77 |
|
Other funds holding VRTX
VCM
VPM
Goldman Sachs's VRTX Position: Q1 2026 in Review
Goldman Sachs increased its Vertex Pharmaceuticals (VRTX) stake by 38% in Q1 2026, buying an estimated $310M and bringing the position to 2,417,875 shares worth $1.08B. The position accounts for 0.12% of the portfolio, ranked #152.
Goldman Sachs first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Goldman Sachs held 2,417,875 shares of Vertex Pharmaceuticals worth $1.08B as of Q1 2026.
- Goldman Sachs bought 663,757 Vertex Pharmaceuticals shares in Q1 2026, an estimated $310M.
- Vertex Pharmaceuticals made up 0.12% of Goldman Sachs's portfolio in Q1 2026, its #152 holding.
- Goldman Sachs first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.